scholarly journals A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure

2006 ◽  
Vol 48 (5) ◽  
pp. 992-998 ◽  
Author(s):  
Gabriele Fragasso ◽  
Altin Palloshi ◽  
Patrizia Puccetti ◽  
Carmen Silipigni ◽  
Alessandra Rossodivita ◽  
...  
Author(s):  
Giuseppe Rosano ◽  
Andrew Coats

Heart failure is associated with altered cardiac metabolism, in part, due to maladaptive mechanisms, in part secondary to comorbidities such as diabetes and ischaemic heart disease. The metabolic derangements taking place in heart failure are not limited to the cardiac myocytes, but extend to skeletal muscles and the vasculature causing changes that contribute to the worsening of exercise capacity. Modulation of cardiac metabolism with partial inhibition of free fatty acid oxidation has been shown to be beneficial in patients with heart failure. At the present, the bulk of evidence for this class of drugs comes from Trimetazidine. Newer compounds partially inhibiting free fatty acid oxidation or facilitating the electron transport on the mitochondrial cristae are in early phase of their clinical development.


2007 ◽  
Vol 4 (4) ◽  
pp. 236-242 ◽  
Author(s):  
Gabriele Fragasso ◽  
Roberto Spoladore ◽  
Giorgio Bassanelli ◽  
Amarild Cuko ◽  
Chiara Montano ◽  
...  

2001 ◽  
Vol 86 (4) ◽  
pp. 1638-1644
Author(s):  
E. E. Blaak ◽  
B. H. R. Wolffenbuttel ◽  
W. H. M. Saris ◽  
M. M. A. L. Pelsers ◽  
A. J. M. Wagenmakers

1994 ◽  
Vol 87 (s1) ◽  
pp. 94-95
Author(s):  
LS Sidossis ◽  
AR Coggan ◽  
A Gastaldelli ◽  
RR Wolfe

Sign in / Sign up

Export Citation Format

Share Document